You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: FasCure Therapeutics LLC Topic: 102
DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: GOBLUE INTERNATIONAL, LLC Topic: 104
Abstract Worry is a habitual thought process that is observed in individuals with anxiety disordersA leading theory posits that although worrying may be unpleasantthe immediate emotions that are avoided by concentrating on worry are often perceived as more aversiveegfearangergriefFrom a mechanistic perspectiveworry is thought to be learned and reinforced in a similar manner to other types of opera ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Vivoscript, Inc. Topic: 200
DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: CASTERBRIDGE PHARMACEUTICALS INC Topic: NIAID
Herpes simplex virusesandHSVHSVcause a wide range of serious diseasesincluding oral genital lesionscorneal blindness and eczema herpeticumHSVand HSVare both transmitted sexually and can infect babies during birthTherapy for HSV relies primarily on nucleoside analogs such as acyclovirACVwhich are insufficiently effectiveand resistant viruses are becoming common among immunosuppressed personsTherefo ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 102
PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Cyteir Therapeutics, Inc. Topic: NCI
DESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: MOUNTAINPASS TECHNOLOGY LLC Topic: 104
DESCRIPTION provided by applicant Approximately of the population experiences elevated depressive symptoms Kubik et al Despite recent research suggesting that overall population mortality would be reduced by if the effects of subthreshold depression could be blocked completely the majority of individuals with elevated depressive symptoms never receive evidence based treat ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: MOUNTAINPASS TECHNOLOGY LLC Topic: 102
DESCRIPTION provided by applicant Treatment for depression is a core health disparity for Latinos in the U S Although U S Latinos are more likely than non Hispanic Whites to experience depression Alegria et al U S Latinos are less than half as likely as Whites to receive evidence based care for depression Lagomasino et al Latinos with elevated depressive symptoms are mos ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: EyeMedix, Inc. Topic: N
DESCRIPTION provided by applicant Retinal diseases including age related macular degeneration AMD diabetic retinopathy DR diabetic macular edema DME and retina vein occlusion RVO are the leading causes of vision loss and blindness in people over years old According to the NEI in nearly million people in the U S suffered from some form of these diseases whose prevalen ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: Op-T-Mune, Inc Topic: NIDDK
AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health